Phase I study of neoadjuvant chemotherapy with gemcitabine and nab paclitaxel for resectable pancreatic cancer.

Phase I study of neoadjuvant chemotherapy with gemcitabine and nab paclitaxel for resectable pancreatic cancer. - NAC with GEM+nab-PTX for pancreatic cancer

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000011062

Enrollment

Registered

2013-07-01

Start date

2013-08-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

resectable pancreatic cancer

Interventions

dose escalation of nab-PTX

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: resectble pancreatic cancer patients withour serious complications

Exclusion criteria

Exclusion criteria: 1) Patients with anti-cancer agent administration in history past 2) Active another cancer 3) Severe complications 4) Patients with interstitial pneumonia or pulmonary fibrosis 5) Active infection 6) Pregnant woman 7) Severe mental disorder 8) Others

Design outcomes

Primary

Measure	Time frame
We can evaluate the sensitivity of anti-cancer drugs at a time when evaluable lesions prior to surgery. Prolongation of disease free survival and overall survival.	—

Countries

Japan

Contacts

Public ContactHidehiro Tajima

Kanazawa University Hospital Hepato-Biliary-Pancreatic Surgery

crc.irb-knz@esct.jp076-265-2362

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026